quinoxalines has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SA; Chen, YC; Chen, YJ; Cheng, CC; Higa, S; Hu, YF | 1 |
1 other study(ies) available for quinoxalines and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin reduces pulmonary vein spontaneous activity through nitric oxide pathway.
Topics: Action Potentials; Androstadienes; Animals; Atrial Fibrillation; Blotting, Western; Electrophysiology; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Heart Atria; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Oxadiazoles; Phosphatidylinositol 3-Kinases; Pulmonary Veins; Quinoxalines; Rabbits; Signal Transduction; Wortmannin | 2009 |